MiniMed Group Inc (NASDAQ:MMED - Get Free Report)'s stock price was up 7.8% during mid-day trading on Wednesday after UBS Group raised their price target on the stock from $25.00 to $28.00. UBS Group currently has a buy rating on the stock. MiniMed Group traded as high as $24.23 and last traded at $24.17. Approximately 434,900 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 1,083,547 shares. The stock had previously closed at $22.42.
A number of other analysts also recently issued reports on MMED. Weiss Ratings raised shares of MiniMed Group from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, July 20th. BTIG Research upped their price objective on shares of MiniMed Group from $25.00 to $28.00 and gave the stock a "buy" rating in a research report on Tuesday. Benchmark restated a "buy" rating on shares of MiniMed Group in a research report on Thursday, June 4th. Piper Sandler restated a "neutral" rating and issued a $16.00 price target on shares of MiniMed Group in a research note on Thursday, June 4th. Finally, Wells Fargo & Company reduced their price target on MiniMed Group from $26.00 to $22.00 and set an "overweight" rating for the company in a report on Thursday, June 4th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, MiniMed Group has a consensus rating of "Moderate Buy" and a consensus price target of $23.08.
Check Out Our Latest Report on MiniMed Group
More MiniMed Group News
Here are the key news stories impacting MiniMed Group this week:
- Positive Sentiment: MiniMed reported fiscal Q1 net sales of $843 million, up 17% year over year, while organic U.S. revenue growth accelerated to 13%. International sales also grew strongly, supporting management’s decision to raise its fiscal 2027 organic revenue-growth guidance. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
- Positive Sentiment: Fiscal Q1 earnings per share of approximately $0 exceeded analyst expectations, contributing to the favorable initial market reaction. Earnings Flash: MiniMed Posts Fiscal Q1 EPS
- Positive Sentiment: MiniMed highlighted progress across its product pipeline, including an FDA submission for MiniMed Fit, a CE Mark for MiniMed Flex, completion of enrollment in the Vivera pivotal trial and IDE approval for a next-generation extended-wear sensor. MiniMed Group Q1 2027 Deep Dive
- Positive Sentiment: Analyst sentiment strengthened after the results. Mizuho raised its target from $21 to $26 with an “outperform” rating; Bank of America lifted its target from $24 to $28 with a “buy” rating; and BTIG also raised its target to $28 and maintained a “buy” rating.
- Negative Sentiment: The reported brokerage consensus target of $21.62 remains below the stock’s recent trading level, indicating that not all analysts have fully reflected the latest operating momentum in their estimates. MiniMed Receives Consensus Target Price from Brokerages
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of MMED. California State Teachers Retirement System acquired a new position in MiniMed Group in the 2nd quarter valued at about $89,000. Readystate Asset Management LP acquired a new stake in MiniMed Group in the second quarter valued at $4,400,000. Washington Growth Strategies LLC acquired a new position in MiniMed Group in the second quarter valued at approximately $397,000. Punch & Associates Investment Management Inc. purchased a new stake in shares of MiniMed Group during the 2nd quarter worth approximately $292,000. Finally, Bank of America Corp DE boosted its stake in MiniMed Group by 377.0% in the second quarter. Bank of America Corp DE now owns 238,819 shares of the company's stock valued at $3,570,000 after acquiring an additional 188,756 shares in the last quarter.
MiniMed Group Price Performance
The stock has a market capitalization of $6.73 billion and a PE ratio of -35.27. The company's 50-day moving average price is $17.65.
MiniMed Group (NASDAQ:MMED - Get Free Report) last posted its quarterly earnings data on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. The business's revenue for the quarter was up 15.6% compared to the same quarter last year. Equities analysts predict that MiniMed Group Inc will post 0.66 EPS for the current year.
MiniMed Group Company Profile
(
Get Free Report)
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider MiniMed Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiniMed Group wasn't on the list.
While MiniMed Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
